Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase 1/2 Recruiting 112 enrolled Perspective Therapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Timeline

Start: 2025-04-28
Primary completion: 2028-01-31
Completion: 2032-05-28

Publications

Fabian D, Levy MS, Piecoro DW, Napier D, Miller RW, Kunos CA. Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer. Front Oncol. 2026 Jun 1;16:1799494. doi: 10.3389/fonc.2026.1799494. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[203Pb]Pb-PSV359	Diagnostic / imaging agent	259 mbq	Intravenous
Subject	[212Pb]Pb-PSV359	Unknown	—	Intravenous

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications